Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

196
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
196
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

172
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
172
Carbohydrate Metabolism01:36

Carbohydrate Metabolism

11.1K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
11.1K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

2.4K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.4K
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

283
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
283

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Continuous Intraperitoneal Insulin Infusion for People With Type 1 Diabetes: A Literature Review and International Position Statement.

Diabetes, obesity & metabolism·2026
Same author

Percent Time Below Range Is Strongly Associated with Clinically Important Level 2 Hypoglycemia Events in Individuals with Type 1 Diabetes.

Diabetes technology & therapeutics·2026
Same author

Impact of Early Initiation of Automated Insulin Delivery on Glycemia Two Years from Type 1 Diabetes Diagnosis.

Hormone research in paediatrics·2026
Same author

Letter: Treatment of Type 2 Diabetes in the United States: 2025.

Diabetes technology & therapeutics·2026
Same author

Raising the Bar: High Time in Range During the First Year of Diagnosis of Type 1 Diabetes in Children and Adolescents Using Automated Insulin Delivery with Intense Support.

Diabetes technology & therapeutics·2026
Same author

Swimming With the Omnipod 5 Automated Insulin Delivery System: An Observational Investigation of Swimmers With Type 1 Diabetes in the Omnipod 5 Pivotal Trial.

Diabetes, obesity & metabolism·2026

Related Experiment Video

Updated: Jul 2, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.8K

Use of the Community-Derived Open-Source Automated Insulin Delivery Loop System in Type 2 Diabetes.

Colleen Bauza1, Lauren G Kanapka1, Ellis Greene1

  • 1JAEB Center for Health Research, Tampa, Florida, USA.

Diabetes Technology & Therapeutics
|February 22, 2024
PubMed
Summary

The open-source Loop hybrid closed-loop system shows promise for managing type 2 diabetes (T2D). This study found improved hemoglobin A1c and time in range with minimal hypoglycemia in T2D users.

Keywords:
AdultHybrid closed loopOpen sourceType 2 diabetestime in range

More Related Videos

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device
07:55

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device

Published on: January 26, 2010

11.9K
Three-dimensional Printing of Thermoplastic Materials to Create Automated Syringe Pumps with Feedback Control for Microfluidic Applications
09:08

Three-dimensional Printing of Thermoplastic Materials to Create Automated Syringe Pumps with Feedback Control for Microfluidic Applications

Published on: August 30, 2018

12.4K

Related Experiment Videos

Last Updated: Jul 2, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

18.8K
A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device
07:55

A Multi-Parametric Islet Perifusion System within a Microfluidic Perifusion Device

Published on: January 26, 2010

11.9K
Three-dimensional Printing of Thermoplastic Materials to Create Automated Syringe Pumps with Feedback Control for Microfluidic Applications
09:08

Three-dimensional Printing of Thermoplastic Materials to Create Automated Syringe Pumps with Feedback Control for Microfluidic Applications

Published on: August 30, 2018

12.4K

Area of Science:

  • Endocrinology
  • Diabetes Technology
  • Artificial Pancreas Systems

Background:

  • Limited data exist on the use of the open-source Loop hybrid closed-loop controller in individuals with type 2 diabetes (T2D).
  • The Loop system is a community-developed automated insulin delivery system.

Purpose of the Study:

  • To investigate the effectiveness and safety of the Loop system in individuals with T2D.
  • To assess glycemic control parameters, including hemoglobin A1c and time in range, in T2D patients using Loop.

Main Methods:

  • An observational study involving individuals with T2D using the Loop system.
  • Data collected from seven eligible participants who used the Loop algorithm.
  • Analysis of self-reported hemoglobin A1c, time in range (70-180 mg/dL), and hypoglycemia events.

Main Results:

  • Mean hemoglobin A1c decreased from 7.3% to 6.0% after initiating Loop.
  • Time in range (70-180 mg/dL) improved from 84% to 93%.
  • Extremely low rates of hypoglycemia were observed, with no severe hypoglycemia or diabetic ketoacidosis events reported.

Conclusions:

  • The Loop system appears effective and safe for individuals with T2D, based on preliminary data.
  • Larger-scale studies are warranted to further evaluate the Loop system's efficacy in the T2D population.
  • The findings support the potential of closed-loop systems in managing type 2 diabetes.